Delving into the Latest Updates on Z-100 with Synapse

Overview

Basic Info

Drug Type

Biological products

Synonyms

Ancer20, SSM, 结核杆菌热水提取物

+ [2]

Target-

Mechanism

Immunomodulators

Therapeutic Areas

Hemic and Lymphatic Diseases

Active Indication

Leukopenia

Inactive Indication

HIV InfectionsLocally Advanced Cervical Carcinoma

Originator Organization

Zeria Usa, Inc.

Active Organization

Zeria Usa, Inc.

Inactive Organization

Zeria Pharmaceutical Co., Ltd.

Drug Highest PhaseApproved

First Approval Date

JP (26 Aug 1991),

Leukopenia

Regulation-

Login to view timeline

This study is a phase III, multicenter, double-blind, placebo-controlled, parallel group comparative study to evaluate the efficacy and safety of Z-100 with primary uterine cervical cancer on radiotherapy. The study will use a central randomization with a dynamic allocation using biased coin minimization.

Start Date01 Dec 2014

Sponsor / Collaborator

Zeria Pharmaceutical Co., Ltd.

JPRN-JapicCTI-121893 / Unknown statusNot Applicable

Clinical Pharmacology Study of Z-100 - Study on Immunological Parameter in Healthy Adult -

Start Date12 Jul 2012

Sponsor / Collaborator

Zeria Pharmaceutical Co., Ltd.

100 Clinical Results associated with Z-100

Login to view more data

100 Translational Medicine associated with Z-100

Login to view more data

100 Patents (Medical) associated with Z-100

Login to view more data

223

Literatures (Medical) associated with Z-100

01 Nov 2024·Operative Dentistry

Bacterial Adhesion and In Situ Biodegradation of Preheated Resin Composite Used as a Luting Agent for Indirect Restorations

Article

Author: Gonçalves, GGA ; Monteiro, GQdeM ; De Brito, OFF ; Bezerra, ALCA ; Alves, LC ; Stamfor, TCM

SUMMARYObjective:To evaluate surface roughness and bacterial adhesion after in situ biodegradation of the cementation interface of indirect restorations cemented with preheated resin composite.Methods and Materials:Resin composite blocks (Z250XT/3M ESPE) were cemented to bovine enamel (7 × 2.5 × 2 mm) using preheated microhybrid resin composites: (1) Filtek Z100 (3M ESPE) (Z100); (2) Gradia Direct X (GC America) (GDX); and (3) Light-cured resin cement RelyX Veneer (3M ESPE) (RXV) (n=21). The resin composites were preheated on a heating device (HotSet, Technolife) at 69°C for 30 minutes. Disk-shaped specimens (7 × 1.5 mm) were made for biodegradation analysis with the luting agents (n=25). The in situ phase consisted of 20 volunteers’ using an intraoral palatal device for 7 days. Each device had six cylindrical wells for the blocks and the disk-shaped specimens. Biodegradation was evaluated through surface roughness (Ra), scanning electron microscopy (SEM) micromorphological analysis, and colony-forming unit (CFU) count. The film thickness of the luting agents was also measured under stereomicroscopy.Results:Increased surface roughness was observed after the cariogenic challenge without differences between the luting agents. Higher variation and surface flaws suggestive of particulate detachment were observed for Z100. No differences were observed in CFU counts.Conclusions:All materials underwent surface biodegradation, and the surface roughness of the resin cements was similar to or lower than that of the preheated resin composites. The resin composites’ film thickness was thicker than that of the resin cement. Clinicians should be aware of these factors when choosing the use of preheated resin composite since it can lead to reduced longevity of the cementation interface and, therefore, restorations.

19 Oct 2024·British Journal of Cancer

Cost-effectiveness of point of care smoking cessation interventions in oncology clinics

Article

Author: Thavorn, Kednapa ; Grant, Alyssa ; Hurley, Kelly ; Warren, Graham W ; Mullen, Kerri A ; Kumar, Eshwar ; Hewitson, Shelley ; Scoville, Joshua

AbstractBackgroundWe examined the cost-effectiveness of providing systematic smoking cessation interventions to oncology patients at point-of-care.MethodsA decision analytic model was completed from the healthcare payer’s perspective and included all incident cancer cases involving patients who smoke in New Brunswick, Canada (n = 1040), cancer site stratifications, and risks of mortality, continued smoking, and cancer treatment failure over one year. Usual care (no cessation support) was compared to the standard Ottawa Model for Smoking Cessation (OMSC) intervention, and to OMSC plus unlimited cost-free stop smoking medication (OMSC + SSM), including nicotine replacement therapy, varenicline, or bupropion. Primary outcomes were incremental cost per quit (ICQ) and incremental cost per cancer treatment failure avoided (ICTFA).ResultsThe ICQ was $C143 and ICTFA $C1193 for standard OMSC. The ICQ was $C503 and ICTFA was $C5952 for OMSC + SSM. The number needed to treat (NNT) to produce one quit was 9 for standard OMSC and 4 for OMSC + SSM, and the NNT to avoid one first-line treatment failure was 78 for OMSC and 45 for OMSC + SSM. Both were cost-effective in 100% of 1000 simulations.ConclusionsGiven the high clinical benefits and low incremental costs, systematic smoking cessation interventions should be a standard component of first-line cancer treatment.

01 Oct 2024·European Journal of Public Health

Are educational aspirations associated with susceptibility to smoking, e-cigarette use, and smokeless tobacco use in adolescence?

Article

Author: Ruokolainen, Otto ; Ollila, Hanna ; Konttinen, Hanna ; Karvonen, Sakari

AbstractThe early socio-economic differences in smoking build on the interplay between individual-, family-, peer-, and school-related factors. The present study aimed to add knowledge to this by examining susceptibility to smoking (S-SM), electronic cigarette (e-cigarette) use (S-EC), and smokeless tobacco (snus) use (S-SN) by educational aspirations in a country with advanced tobacco control policies. National cross-sectional School Health Promotion study survey was conducted among 8.–9. grade students (av. 15-year-olds) in 2017 with no prior smoking (n = 47 589), e-cigarette use (n = 49 382), or snus use (n = 53 335). Gender-stratified, age-adjusted multilevel logistic regression analyses with S-SM, S-EC, and S-SN were considered as outcomes and student- and school-level (aggregated) factors were considered as independent variables. The highest prevalence was observed for S-EC (girls 29%, boys 35%), followed by S-SM (16%, 15%) and S-SN (10%, 16%). Compared to those planning for general upper secondary education, S-SM was the highest for those without educational aspirations (OR = 1.20, 95% CI = 1.04–1.40), S-EC for those planning for vocational education [1.15 (1.05–1.25)], and S-SN for those planning for extra year/discontinuation [1.65 (1.04–2.60)] among girls. Among boys, both S-SM [1.37 (1.23–1.52)] and S-EC [1.19 (1.09–1.29)] were the highest among those planning for vocational education, with no clear associations with S-SN. Current other tobacco/e-cigarette use [OR range 1.27–8.87], positive attitude towards product use in one’s age group [3.55–6.63], and liking school [0.58–0.68] consistently associated with susceptibility. Students not planning for academically oriented education had higher susceptibility to different nicotine products. High S-EC warrants monitoring to strengthen policy evaluation and prevention.

100 Deals associated with Z-100

Login to view more data

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Leukopenia	JP	Zeria Usa, Inc.	26 Aug 1991

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Locally Advanced Cervical Carcinoma	Preclinical	MY	Zeria Pharmaceutical Co., Ltd.	01 Dec 2014
HIV Infections	Preclinical	US	Zeria Pharmaceutical Co., Ltd.	31 Aug 2001
Locally Advanced Cervical Carcinoma	Discovery	SG	Zeria Pharmaceutical Co., Ltd.	01 Dec 2014
Locally Advanced Cervical Carcinoma	Discovery	TH	Zeria Pharmaceutical Co., Ltd.	01 Dec 2014
Locally Advanced Cervical Carcinoma	Discovery	JP	Zeria Pharmaceutical Co., Ltd.	01 Dec 2014
Locally Advanced Cervical Carcinoma	Discovery	TW	Zeria Pharmaceutical Co., Ltd.	01 Dec 2014
Locally Advanced Cervical Carcinoma	Discovery	VN	Zeria Pharmaceutical Co., Ltd.	01 Dec 2014
Locally Advanced Cervical Carcinoma	Discovery	KR	Zeria Pharmaceutical Co., Ltd.	01 Dec 2014

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


JPRN-C000000221 (JGOG-DT101, ASCO2013)	Phase 3	Uterine Cervical Cancer	249	Z-100 0.2 μg	(gboyknwvwk) = chvibhdzbn zsvzxvqntx (crystmcyvr, 66.4 - 82.8)	Positive	20 May 2013
				Placebo	(gboyknwvwk) = mkotehthhk zsvzxvqntx (crystmcyvr, 56.2 - 73.8)